Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Newron Pharmaceuticals S.p.A.
  6. Summary
    NWRN   IT0004147952

NEWRON PHARMACEUTICALS S.P.A.

(NWRN)
  Report
Delayed Quote. Delayed Swiss Exchange - 09/17 11:31:41 am
2.06 CHF   --.--%
09/16NEWRON PHARMACEUTICALS S P A : Announces Half-Year 2021 Results
BU
09/16NEWRON PHARMACEUTICALS S P A : Trims Loss As Revenue Climbs in H1
MT
09/16Newron announces Half-Year 2021 results
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
2.15(c) 2.12(c) 2.06(c) 2.06(c) 2.06(c) Last
5 712 11 676 33 510 19 378 8 644 Volume
+1.90% -1.40% -2.83% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 6,83 M 8,01 M 8,01 M
Net income 2021 -18,1 M -21,2 M -21,2 M
Net Debt 2021 12,0 M 14,0 M 14,0 M
P/E ratio 2021 -1,85x
Yield 2021 -
Sales 2022 19,3 M 22,7 M 22,7 M
Net income 2022 -14,1 M -16,6 M -16,6 M
Net Debt 2022 38,7 M 45,3 M 45,3 M
P/E ratio 2022 -2,35x
Yield 2022 -
Capitalization 33,6 M 39,5 M 39,4 M
EV / Sales 2021 6,67x
EV / Sales 2022 3,74x
Nbr of Employees 23
Free-Float 93,8%
More Financials
Company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Ratings of Newron Pharmaceuticals S.p.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NEWRON PHARMACEUTICALS S.P.A.
09/16NEWRON PHARMACEUTICALS S P A : Announces Half-Year 2021 Results
BU
09/16NEWRON PHARMACEUTICALS S P A : Trims Loss As Revenue Climbs in H1
MT
09/16Newron announces Half-Year 2021 results
DJ
09/16NEWRON PHARMACEUTICALS S P A : announces Half-Year 2021 results
EQ
09/16PRESS RELEASE : Newron announces Half-Year 2021 -2-
DJ
09/16PRESS RELEASE : Newron announces Half-Year 2021 results
DJ
09/07NEWRON PHARMACEUTICALS S P A : Gets $9 Million Under Financing Deal With Europea..
MT
09/06Newron Receives Fourth Tranche from Financing Agreement with European Investm..
DJ
09/06PRESS RELEASE : Newron Receives Fourth Tranche from Financing Agreement with Eur..
DJ
09/06NEWRON PHARMACEUTICALS S P A : Receives Fourth Tranche from Financing Agreement ..
BU
09/06NEWRON PHARMACEUTICALS S P A : Receives Fourth Tranche from Financing Agreement ..
EQ
09/06NEWRON PHARMACEUTICALS S P A : Initiates First Potentially Pivotal Study with Ev..
BU
09/06NEWRON PHARMACEUTICALS S P A : Launches First Trial For Schizophrenia Treatment
MT
09/06Newron Initiates First Potentially Pivotal Study with Evenamide in Patients w..
DJ
09/06PRESS RELEASE : Newron Initiates First Potentially Pivotal Study with Evenamide ..
DJ
More news
News in other languages on NEWRON PHARMACEUTICALS S.P.A.
09/16Newron contre-attaque les producteurs de génériques aux Etats-Unis
09/16Newron dämmt Verlust im ersten Semester 2021 leicht ein - Projekte im Plan
09/16Newron Pharmaceuticals réduit sa perte alors que ses revenus augmentent au pr..
09/16Newron berichtet über -2-
09/16Newron berichtet über Halbjahresergebnis 2021
More news
Chart NEWRON PHARMACEUTICALS S.P.A.
Duration : Period :
Newron Pharmaceuticals S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS S.P.A.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,88 €
Average target price 7,14 €
Spread / Average Target 279%
EPS Revisions
Managers and Directors
Stefan Weber Chief Executive Officer & Director
Roberto Galli Vice President-Finance
Ulrich Köstlin Non-Executive Chairman
Ravi Anand Chief Medical Officer
Luca Benatti Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
NEWRON PHARMACEUTICALS S.P.A.-4.19%39
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336